Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

GENERIC DRUG USE WILL BE MANDATED BY ALL HEALTH INSURANCE PROGRAMS providing Rx drug benefits, Rep. Waxman (D-Calif.) predicted in a May 21 speech to the Natl. Assn. of Retail Druggists (NARD). "I expect all health insurance plans will insist that generic drugs, whenever they're available, be used instead of brandname drugs," Waxman said. Speaking at NARD's May 20-22 legislative conference, the congressman predicted that "many of the insurance companies that have not in the past mandated the use of generic drugs will in fact mandate the use of those drugs because the savings from them will be much too attractive." He cited estimates that the post-1962 ANDA law he sponsored last year will result in Rx drug cost savings to consumers of "about $1 bil. over the next decade." Noting that organized pharmacy has voiced concerns that the Maximum Allowable Cost (MAC) Rx drug reimbursement program under Medicaid "doesn't adequately reflect the limitations you [pharmacists] face in getting drugs at costs set by the program," Waxman declared that problems associated with MAC will "become even more pressing soon, as the generic drug law . . . goes fully into effect."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts